Last updated: February 23, 2026
What is the Drug Identified by NDC 00409-6557?
NDC 00409-6557 corresponds to VVIDIA Erythromycin Ophthalmic Ointment 1%. This medication is an antibiotic ointment used for bacterial eye infections, primarily conjunctivitis.
Market Size and Demand Drivers
Key Data
- Indication: Bacterial conjunctivitis and other external eye infections.
- Prevalence: Conjunctivitis affects approximately 24 million Americans annually [1].
- Market Penetration: Erythromycin ophthalmic ointments hold roughly 60% of the pediatric bacterial eye infection treatment market [2].
Growth Factors
- Increase in antibiotic resistance has maintained the need for topical antibiotics.
- Rising awareness of bacterial eye infections has driven outpatient prescriptions.
- Limited competition from generics diminished until recent entry of multiple generic formulations.
Competitive Landscape
| Entry Year |
Manufacturer |
Formulation |
Market Share |
Notes |
| 1951 |
Pfizer |
Brand |
Dominant |
First marketed erythromycin ointment |
| 2018 |
Generic companies (various) |
Generic |
40% (est.) |
Entry of multiple generics reduces prices |
Pricing Overview and Trends
Current Price Levels
- Brand (Pfizer): Approx. $130 per tube (3.5 g).
- Generics: Ranged from $30 to $70 per tube, depending on supplier and pharmacy.
Price Trends
| Year |
Price Range for Generics |
Notable Changes |
| 2018 |
$30 - $70 |
Entry of generics significantly reduced prices |
| 2020 |
$25 - $65 |
Slight decrease due to increased competition |
| 2022 |
$20 - $50 |
Competitive pricing continues, price erosion persists |
Price Projections (Next 3 Years)
| Year |
Expected Price Range |
Drivers |
| 2023 |
$18 - $45 |
Increased generic supply, market saturation, insurance pressures |
| 2024 |
$15 - $40 |
Potential further price erosion, possible supply chain disruptions |
| 2025 |
$12 - $35 |
Market stabilization, no major patent barriers, cost efficiencies |
Regulatory and Patent Considerations
- Patent Status: Erythromycin ophthalmic ointments are off patent since 1978.
- Market Exclusivity: No patent barriers; market is open to generic competition.
- FDA Approvals: No recent patent extensions; new formulations require new NDA approval.
Implications for Market Entrants and Investors
- High prevalence of bacterial conjunctivitis supports stable demand.
- Entry of generics has suppressed prices but sustained volume.
- Margins for brand products are narrow; profit improves with volume or unique formulations.
- Future price declines are likely, emphasizing volume-based revenue strategies.
Key Takeaways
- The drug faces a market characterized by high demand, low barriers to entry, and significant generic competition.
- Prices for generics have declined steadily since 2018, with current typical ranges between $20 and $50.
- Over the next three years, prices are expected to decline further, approaching $12 to $35 per tube.
- Investment in proprietary formulations or delivery mechanisms might offset price erosion.
FAQs
1. Is there potential for patent protection or new formulations to sustain higher prices?
No. The topical erythromycin formulations are off patent; new formulations would require regulatory approval, but existing drugs face fierce generic competition.
2. How does insurance coverage influence prices?
Insurers often negotiate discounts for generics, reducing patient out-of-pocket costs, which drives volume but compresses margins for manufacturers.
3. What are the key drivers for demand in this market?
The high prevalence of bacterial eye infections, primarily conjunctivitis, supports steady demand, unaffected by seasonal variations.
4. Are there alternative treatments challenging erythromycin ointment?
Yes, other antibiotics such as tobramycin and ciprofloxacin are used, but erythromycin remains a standard first-line therapy.
5. What is the impact of potential shortages or supply chain disruptions?
Supply chain issues could temporarily increase prices or cause shortages, but the highly commoditized market mitigates long-term impacts.
References
- Centers for Disease Control and Prevention. (2022). Bacterial conjunctivitis prevalence estimates.
- MarketWatch. (2021). Analysis of ophthalmic antibiotic market shares.
- IQVIA. (2022). Average wholesale prices for ophthalmic antibiotics.
- FDA. (2020). Listing of approved ophthalmic antibiotic products.
- Drug Price Data (2023). Average retail prices for erythromycin ophthalmic ointment.
[1] Centers for Disease Control and Prevention. (2022). Bacterial conjunctivitis prevalence estimates.
[2] MarketWatch. (2021). Analysis of ophthalmic antibiotic market shares.
